Diligence memo · auto-generated · as of July 2, 2026
Carmell Therapeutics Corp
Carmell Therapeutics Corp looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Carmell Therapeutics Corp operates in Biotechnology, based in PITTSBURGH.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Carmell Therapeutics Corp has raised $16M in disclosed capital across 11 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.2M on 2018-07-09.
Most recent recorded round closed around 2019-09-25.
Valuation (modeled)modeled
Provath models Carmell Therapeutics Corp at approximately $86M (range $2.6M–$469M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.48× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 6.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 64% of Biotechnology peers (4293 compared).
Modeled value ranks above 55% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
18 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.